13 results on '"Francine K. Welty"'
Number of results to display per page
Search Results
2. A Clinician's Guide to Healthy Eating for Cardiovascular Disease Prevention
- Author
-
Vincent A. Pallazola, MD, Dorothy M. Davis, MSN, RN, Seamus P. Whelton, MD, MPH, Rhanderson Cardoso, MD, Jacqueline M. Latina, MD, Erin D. Michos, MD, MHS, Sudipa Sarkar, MD, Roger S. Blumenthal, MD, Donna K. Arnett, PhD, MSPH, Neil J. Stone, MD, and Francine K. Welty, MD, PhD
- Subjects
Medicine (General) ,R5-920 - Abstract
Despite continued advances in health care, the cardiovascular disease (CVD) mortality rate has plateaued in recent years and appears to be trending upward. Poor diet is a leading cause of obesity and type 2 diabetes mellitus, which are leading contributors to CVD morbidity and mortality. Although dietary modification is a cornerstone of CVD prevention, implementation in clinical practice is limited by inadequate formal training in nutrition science. In this report, we review the individual components of a heart-healthy diet, evidence-based dietary recommendations, and the impact of diet on CVD risk factor prevention and management. Furthermore, we examine the unique difficulties of dietary counseling in low-socioeconomic-status environments and provide an evidence-based approach to better serve these populations. We utilized PubMed searches in adults with no date restriction with the following search terms: “carbohydrate,” “fat,” protein,” “DASH,” “Mediterranean,” “plant-based,” “vegetarian,” “cardiovascular disease,” “obesity,” “weight loss,” “diabetes,” “socioeconomic status,” and “race.” In this review, we demonstrate that patients should focus on implementing a general diet plan that is high in fruits, whole grains, legumes, and nonstarchy vegetables while low in trans-fats, saturated fats, sodium, red meat, refined carbohydrates, and sugar-sweetened beverages. The Dietary Approaches to Stop Hypertension, Mediterranean, and vegetarian diets have the most evidence for CVD prevention. Clinicians should understand the barriers that patients may face in terms of access to healthy dietary choices. Further research is needed to determine the dietary changes that are most economically, socioculturally, and logistically feasible to reduce these barriers. Improvement in diet is a public health priority that can lead to a significant population-level reduction in CVD morbidity and mortality. It is imperative that clinicians understand current dietary practice guidelines and implement evidence-based dietary counseling in those at high risk for CVD.
- Published
- 2019
- Full Text
- View/download PDF
3. Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects
- Author
-
Esther M.M. Ooi, Alice H. Lichtenstein, John S. Millar, Margaret R. Diffenderfer, Stefania Lamon-Fava, Helen Rasmussen, Francine K. Welty, P. Hugh R. Barrett, and Ernst J. Schaefer
- Subjects
fatty acids ,hypercholesterolemia ,apolipoproteins ,dyslipidemias ,fish oil ,lipoproteins/linetics ,Biochemistry ,QD415-436 - Abstract
The effects of Therapeutic Lifestyle Change (TLC) diets, low and high in dietary fish, on apolipoprotein metabolism were examined. Subjects were provided with a Western diet for 6 weeks, followed by 24 weeks of either of two TLC diets (10/group). Apolipoprotein kinetics were determined in the fed state using stable isotope methods and compartmental modeling at the end of each phase. Only the high-fish diet decreased median triglyceride-rich lipoprotein (TRL) apoB-100 concentration (−23%), production rate (PR, −9%), and direct catabolism (−53%), and increased TRL-to-LDL apoB-100 conversion (+39%) as compared with the baseline diet (all P < 0.05). This diet also decreased TRL apoB-48 concentration (−24%), fractional catabolic rate (FCR, −20%), and PR (−50%) as compared with the baseline diet (all P < 0.05). The high-fish and low-fish diets decreased LDL apoB-100 concentration (−9%, −23%), increased LDL apoB-100 FCR (+44%, +48%), and decreased HDL apoA-I concentration (−15%, −14%) and PR (−11%, −12%) as compared with the baseline diet (all P < 0.05). On the high-fish diet, changes in TRL apoB-100 PR were negatively correlated with changes in plasma eicosapentaenoic and docosahexaenoic acids. In conclusion, the high-fish diet decreased TRL apoB-100 and TRL apoB-48 concentrations chiefly by decreasing their PR. Both diets decreased LDL apoB-100 concentration by increasing LDL apoB-100 FCR and decreased HDL apoA-I concentration by decreasing HDL apoA-I PR.
- Published
- 2012
- Full Text
- View/download PDF
4. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
- Author
-
John S. Millar, Margaret E. Brousseau, Margaret R. Diffenderfer, P. Hugh R. Barrett, Francine K. Welty, Jeffrey S. Cohn, Aisha Wilson, Megan L. Wolfe, Chorthip Nartsupha, Peter M. Schaefer, Andres G. Digenio, James P. Mancuso, Gregory G. Dolnikowski, Ernst J. Schaefer, and Daniel J. Rader
- Subjects
very low density lipoproteins ,triglyceride ,low density lipoproteins ,lipoprotein kinetics ,Biochemistry ,QD415-436 - Abstract
Cholesteryl ester transfer protein (CETP) inhibition leads to changes in lipoprotein metabolism. We studied the effect of the CETP inhibitor torcetrapib on VLDL apolipoprotein E (apoE) metabolism. Subjects, pretreated with atorvastatin (n = 9) or untreated (n = 10), received placebo followed by torcetrapib (4 weeks each). After each treatment, subjects underwent a primed-constant infusion of D3-leucine to determine the VLDL apoE production rate (PR) and fractional catabolic rate (FCR). Torcetrapib alone reduced the VLDL apoE pool size (PS) (−28%) by increasing the VLDL apoE FCR (77%) and leaving the VLDL apoE PR unchanged. In subjects pretreated with atorvastatin, torcetrapib increased the VLDL apoE FCR (25%) and PR (21%). This left the VLDL apoE PS unchanged but increased the VLDL apoE content, likely enhancing VLDL clearance and reducing LDL production in this group. Used alone, torcetrapib reduces the VLDL apoE PS by increasing the apoE FCR while leaving the VLDL apoE content unchanged. In contrast, torcetrapib added to atorvastatin treatment increases both the VLDL apoE FCR and PR, leaving the VLDL apoE PS unchanged. Adding torcetrapib to atorvastatin treatment increases the VLDL apoE content, likely leading to decreased conversion of VLDL to LDL, reduced LDL production, and lower levels of circulating VLDL and LDL.
- Published
- 2008
- Full Text
- View/download PDF
5. LC-MS-based method for the qualitative and quantitative analysis of complex lipid mixtures
- Author
-
Ulf Sommer, Haya Herscovitz, Francine K. Welty, and Catherine E. Costello
- Subjects
low density lipoprotein ,intermediate density lipoprotein ,normal-phase high-performance liquid chromatography-mass spectrometry ,reversed-phase liquid chromatography-tandem mass spectrometry ,familial hypobetalipoproteinemia ,Biochemistry ,QD415-436 - Abstract
A simple and robust LC-MS-based methodology for the investigation of lipid mixtures is described, and its application to the analysis of human lipoprotein-associated lipids is demonstrated. After an optional initial fractionation on Silica 60, normal-phase HPLC-MS on a YMC PVA-Sil column is used first for class separation, followed by reversed-phase LC-MS or LC-tandem mass spectrometry using an Atlantis dC18 capillary column, and/or nanospray MS, to fully characterize the individual lipids. The methodology is applied here for the analysis of human apolipoprotein B-associated lipids. This approach allows for the determination of even low percentages of lipids of each molecular species and showed clear differences between lipids associated with apolipoprotein B-100-LDL isolated from a normal individual and those associated with a truncated version, apolipoprotein B-67-containing lipoproteins, isolated from a homozygote patient with familial hypobetalipoproteinemia. The methods described should be easily adaptable to most modern MS instrumentation.
- Published
- 2006
- Full Text
- View/download PDF
6. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins
- Author
-
Wanda Vélez-Carrasco, Alice H. Lichtenstein, P. Hugh R. Barrett, Zhiyong Sun, Gregory G. Dolnikowski, Francine K. Welty, and Ernst J. Schaefer
- Subjects
apoA-I ,apoB-48 ,kinetics ,stable isotopes ,TRL ,compartmental analysis ,Biochemistry ,QD415-436 - Abstract
Stable isotope methodology was used to determine the kinetic behavior of apolipoprotein (apo) A-I within the triglyceride-rich lipoprotein (TRL) fraction and to compare TRL apoA-I kinetics with that of apoA-I in high density lipoprotein (HDL) and TRL apoB-48. Eight subjects (5 males and 3 females) over the age of 40 were placed on a baseline average American diet and after 6 weeks received a primed-constant infusion of [5,5,5-2H3]-l-leucine for 15 h while consuming small hourly meals of identical composition. HDL and TRL apoA-I and TRL apoB-48 tracer/tracee enrichment curves were obtained by gas chromatography–mass spectrometry. Data were fitted to a compartmental model to determine the fractional secretion rates of apoA-I and apoB-48 within each lipoprotein fraction. Mean plasma apoA-I levels in TRL and HDL fractions were 0.204 ± 0.057 and 134 ± 15 mg/dl, respectively. The mean fractional catabolic rate (FCR) of TRL apoA-I was 0.250 ± 0.069 and HDL apoA-I was 0.239 ± 0.054 pools/day, with mean estimated residence times (RT) of 4.27 and 4.37 days, respectively. The mean TRL apoB-48 FCR was 5.2 ± 2.0 pools/day and the estimated mean RT was 5.1 ± 1.8 h. Our results indicate that apoA-I is catabolized at a slower rate than apoB-48 within TRL, and that apoA-I within TRL and HDL fractions are catabolized at similar rates.—Vélez-Carrasco, W., A. H. Lichtenstein, P. H. R. Barrett, Z. Sun, G. G. Dolnikowski, F. K. Welty, and E. J. Schaefer. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins. J. Lipid Res. 1999. 40: 1695–1700.
- Published
- 1999
- Full Text
- View/download PDF
7. Familial hypobetalipoproteinemia and abetalipoproteinemia
- Author
-
Francine K. Welty
- Published
- 2022
- Full Text
- View/download PDF
8. Contributors
- Author
-
Luis G. Aguayo, Marium Ahmed, Mohamed H. Ahmed, Musaab Ahmed, Hélio M.T. Albuquerque, Alicia Alonso, Rana Ashkar, Fodil Azzaz, Carlos J. Baier, Francisco J. Barrantes, Małgorzata Bednarska-Makaruk, Andrew S. Bell, Asier Benito-Vicente, Michael F. Brown, Anna N. Bukiya, Carlos F. Burgos, Henri Chahinian, Waranya Chatuphonprasert, Parkson Lee-Gau Chong, Arrigo F.G. Cicero, Ivan R. Cincione, Tatiana M. Clemente, George A. Cook, Zoe Cournia, Coralie Di Scala, Milka Doktorova, Fathima T. Doole, Alex M. Dopico, Alexandros A. Drosos, Hong Du, Marshall B. Elam, Isabella Ellinger, Jacques Fantini, Filipe Ferrari, Unai Galicia-Garcia, Aritz B. García-Arribas, Stacey D. Gilk, Félix M. Goñi, Juliana Gonzalez-Sanmiguel, Gregory A. Grabowski, Sudipta Gupta, Tina Herfel, DanRong Hu, Juyang Huang, Shifa Jebari-Benslaiman, Qiu-Xing Jiang, Samantha Karr, George Khelashvili, Sofia Kiriakidi, Tamas Kovacs, Teshani Kumarage, Claude K. Lardinois, Asier Larrea-Sebal, Irena Levitan, Hanxuan Li, Wei Li, Falk W. Lohoff, Agnieszka Ługowska, Cesar Martin, Vítor M. Martins, Thomas Mavromoustakos, Mark T. Mc Auley, Dushyant Mital, Bob M. Moore, Amy E. Morgan, Ole G. Mouritsen, Steven Mysiewicz, Kelsey C. North, Emma M. O’Connell, Marta Pasenkiewicz-Gierula, ZhiYong Qian, Jorge P. Roa, Avia Rosenhouse-Dantsker, Clementina M.M. Santos, Artur M.S. Silva, Alexandria Slayden, Ghada A. Soliman, Natalia Stein, Ricardo Stein, Witold K. Subczynski, István P. Sugár, Lajos Szente, Kepa B. Uribe, Zoltan Varga, Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Francine K. Welty, Justyna Widomska, Nouara Yahi, Zdenek Zadak, and Florina Zakany
- Published
- 2022
- Full Text
- View/download PDF
9. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
- Author
-
Peter M. Schaefer, Aisha Wilson, Gregory G. Dolnikowski, Ernst J. Schaefer, John S. Millar, Daniel J. Rader, Margaret E. Brousseau, Jeffrey S. Cohn, Margaret R. Diffenderfer, Andres Digenio, James P. Mancuso, Chorthip Nartsupha, Megan L. Wolfe, P. Hugh R. Barrett, and Francine K. Welty
- Subjects
Apolipoprotein E ,Male ,medicine.medical_specialty ,Very low-density lipoprotein ,Atorvastatin ,QD415-436 ,Lipoproteins, VLDL ,digestive system ,Biochemistry ,chemistry.chemical_compound ,Endocrinology ,Apolipoproteins E ,Internal medicine ,Cholesterylester transfer protein ,medicine ,polycyclic compounds ,Humans ,Pyrroles ,Single-Blind Method ,triglyceride ,Enzyme Inhibitors ,CETP inhibitor ,very low density lipoproteins ,Triglyceride ,biology ,Anticholesteremic Agents ,Torcetrapib ,nutritional and metabolic diseases ,lipoprotein kinetics ,Cell Biology ,Metabolism ,Cholesterol Ester Transfer Proteins ,Kinetics ,chemistry ,Heptanoic Acids ,low density lipoproteins ,biology.protein ,Quinolines ,Drug Therapy, Combination ,Female ,lipids (amino acids, peptides, and proteins) ,medicine.drug - Abstract
Cholesteryl ester transfer protein (CETP) inhibition leads to changes in lipoprotein metabolism. We studied the effect of the CETP inhibitor torcetrapib on VLDL apolipoprotein E (apoE) metabolism. Subjects, pretreated with atorvastatin (n = 9) or untreated (n = 10), received placebo followed by torcetrapib (4 weeks each). After each treatment, subjects underwent a primed-constant infusion of D(3)-leucine to determine the VLDL apoE production rate (PR) and fractional catabolic rate (FCR). Torcetrapib alone reduced the VLDL apoE pool size (PS) (-28%) by increasing the VLDL apoE FCR (77%) and leaving the VLDL apoE PR unchanged. In subjects pretreated with atorvastatin, torcetrapib increased the VLDL apoE FCR (25%) and PR (21%). This left the VLDL apoE PS unchanged but increased the VLDL apoE content, likely enhancing VLDL clearance and reducing LDL production in this group. Used alone, torcetrapib reduces the VLDL apoE PS by increasing the apoE FCR while leaving the VLDL apoE content unchanged. In contrast, torcetrapib added to atorvastatin treatment increases both the VLDL apoE FCR and PR, leaving the VLDL apoE PS unchanged. Adding torcetrapib to atorvastatin treatment increases the VLDL apoE content, likely leading to decreased conversion of VLDL to LDL, reduced LDL production, and lower levels of circulating VLDL and LDL.
- Published
- 2008
10. Contributors
- Author
-
Mansurah A. Abdulazeez, Mahinda Abeywardena, Mujitaba S. Abubakar, G.O. Adegoke, Oluyemisi Elizabeth Adelakun, Shyam S. Agrawal, Francis Agyemang-Yeboah, Cecilia Aiello, Ibironke Adetolu Ajayi, Olubunmi Bolanle Ajayi, Teresa A. Akeng'a, Aderemi Caleb Aladeokin, Mohamed Ali Al-Farsi, Amna Ali, Niloufer Sultan Ali, Ryszard Amarowicz, Sunday J. Ameh, Larissa Lovatto Amorin, B. Andallu, Paula B. Andrade, Sirajudheen Anwar, Harry Archimède, Ignasius Radix Astadi, Everaldo Attard, Marcos Aurélio de Santana, Cecile Badet, Sachin L. Badole, Daniel J. Ballhorn, Monica S. Banach, Douglas C. Baxter, Dorothea Bedigian, Mikhail A. Belozersky, Valerio Berardi, Trust Beta, Aruna Bhatia, Sanjib Bhattacharya, Jitendra D. Bhosale, Sujit K. Bhutia, Hans Konrad Biesalski, Abdullah bin Habeeballah bin Abdullah Juma, Rune Blomhoff, Judith Boateng, Subhash L. Bodhankar, Anders Borgen, Tomasz Brzozowski, H.N. Büyükkartal, Deon V. Canyon, Monica H. Carlsen, Benildo S. Cavada, Pierre Champy, Cheng-Jie Chen, Jianwei Chen, Yong Chen, Eliton Chivandi, Chanya Chaicharoenpong, Yau-Sang Chan, Randy C.F. Cheung, Adriana Chicco, Pei-Yi Chu, M. Carmen Cid, William de Castro Borges, Luis Cisneros-Zevallos, Wayne Coates, Marie M. Cochard, Marina Cocchi, Hatice Çölgeçen, Marina Contini, Rajesh Dabur, Patrick A. Dakia, B. Daramola, Teresa Delgado, Sandhya Desai, Saikat Dewanjee, Giuseppa Di Bella, Irene Dini, Danuta Drozdowicz, Noélia Duarte, Anuradha Dube, Giacomo Dugo, Yakov E. Dunaevsky, null María del Carmen Durán-de-Bazúa, Caterina Durante, Rafael Cypriano Dutra, George A. Dyer, Tsezi A. Egorov, Akram Eidi, Maryam Eidi, Philippe A. Eigenmann, Mohamed Elleuch, Emma Engström, Kennedy H. Erlwanger, Amin Esfahani, Letícia Estevinho, Mohd Fadzelly Abu Bakar, Evandro F. Fang, Fan-Fu Fang, E. Olatunde Farombi, Afrânio G. Fernandes, Maria-José U. Ferreira, Federico Ferreres, Swaran J.S. Flora, Giorgia Foca, Octavio Luiz Franco, Maria Teresa Frangipane, Jeffrey R. Fry, Shin Yee Fung, Magaji Garba, Manohar L. Garg, Mahavir H. Ghante, Hasanah Mohd Ghazali, Kesturu Subbaiah Girish, Daniele Giuffrida, Alexandre Gonçalves Santos, Mónica González, Milton Hércules Guerra de Andrade, Asheesh Gupta, Ashish Deep Gupta, Ella H. Haddad, Bente Lise Halvorsen, Hans-Peter Hanssen, Ken-ichi Hatano, Mahadevappa Hemshekhar, Blanca Hernández-Ledesma, María del Rosario Hernández-Medel, Elisa Yoko Hirooka, Michal Holčapek, Chia-Chien Hsieh, Dur-Zong Hsu, Xiaojie Hu, Wen-Chuan Huang, Uford S. Inyang, Zafar Iqbal, Gerhard Jahreis, Anna Jaromin, David J.A. Jenkins, Sunny Jhamnani, Yueming Jiang, Rod Jones, Rachid Kacem, Monica Kachroo, Daein Kang, Dayanand M. Kannur, Kempaiah Kemparaju, Cyril C.W. Kendall, Natalya V. Khadeeva, Tanvir Khaliq, Ali Khan Khuwaja, David H. Kinder, Jiyoung Kim, Soressa M. Kitessa, Merih Kivanc, Kathryn T. Knecht, Kazunori Koba, U. Koca, Mongomaké Koné, Stanislaw J. Konturek, Mariola Korycińska, Arkadiusz Kozubek, Vera Krimer-Malešević, Nikhil Kumar, A.V. Vinay Kumar, Slawomir Kwiecien, Sze-Kwan Lam, Karen Lapsley, Carl J. Lavie, Sonaly Cristine Leal, Chang Young Lee, John H. Lee, Hyong Joo Lee, Ki Won Lee, Yang Deok Lee, Yann-Lii Leu, Delfín Rodríguez Leyva, Duo Li, Min Li, Xiang Li, Ying Liang, Chang-Quan Ling, Miroslav Lísa, Ming-Yie Liu, Qin Liu, Xianxian Liu, Mario Li Vigni, M. Gloria Lobo, Tirupur Venkatachalam Logaraj, Leonardo Lombardini, Yolanda B. Lombardo, Giovanna Loredana La Torre, Ben O. de Lumen, Xingming Ma, Senka Mađarev-Popović, Maurice Mahieu, Anup Maiti, Tapas K. Maiti, Manisha Deb Mandal, Shyamapada Mandal, Tusharkanti Mandal, Andrea Marchetti, Carine Marie-Magdeleine, Colin R. Martin, Sarfaraz Khan Marwat, Riccardo Massantini, Richard D. Mattes, Richelle S. McCullough, Krystyna Michalak, Richard Milani, Arash Mirrahimi, Tulika Mishra, Pragya Misra, Takuya Miyakawa, Abdulkarim Sabo Mohammed, Maryati Mohamed, Joseph Molnár, Alisa Mori, Siham Mostafa Ali El-Shenawy, Michael Murkovic, Subban Nagarajan, Marcelo H. Napimoga, Tadigoppula Narender, Tzi-Bun Ng, Patrick H.K. Ngai, Nguyen Nguyen, Peter D. Nichols, Julius Enyong Oben, Obiageli O. Obodozie, Steve Ogbonnia, James H. O'Keefe, María Eugenia Oliva, Elisabete Yurie Sataque Ono, Mario Augusto Ono, Ana G. Ortiz-Quezada, Olusegun James Oyelade, Folake Lucy Oyetayo, Yingming Pan, Vidhu Pachauri, Madan Mohan Padhi, Robert Pajdo, Alistair G. Paice, Dilipkumar Pal, Michal Pawlik, Wieslaw W. Pawlik, Patrícia Barbosa Pelegrini, Draginja Peričin, David M. Pereira, José Alberto Pereira, Amorn Petsom, Grant N. Pierce, Alexander M. Popov, Y. Pramodini, Nagendra Prasad, Lu-Ping Qin, Yang Qiu, K. Vijaya Rachel, Ljiljana Radulović, Asmah Rahmat, P.S. Rajini, Deepak Rajpurohit, C.U. Rajeshwari, Elsa Ramalhosa, Gajendra Rao, Lingamallu Jagan Mohan Rao, Nádia Rezende Barbosa Raposo, Francesca Ricci, Gianfranco Risuleo, Simone J. Rochfort, Ilia Rodushkin, Carolina Nachi Rossi, Hafiz Abubaker Saddiqi, Kanagal Sahana, Marcello Saitta, Ibrahim Sani, Nalan Yilmaz Sariozlu, Yoriko Sawano, Ulrich Schäfer, Markus Schmitz-Hübsch, Dante Selenscig, S. Sengottuvelu, Essam Shaalan, John L. Sievenpiper, Simona Sighinolfi, Si Mui Sim, Aline Siqueira Ferreira, Julio A. Solís-Fuentes, Korbua Srichaikul, Welma Stonehouse, M.T. Ravi Subbiah, Katarzyna Suchoszek-Łukaniuk, Reka Szollosi, Nget Hong Tan, Masaru Tanokura, Lorenzo Tassi, Edson H. Teixeira, Christine D. Thomson, Sriniwas Tiwari, Yaya Touré, Alessandro Ulrici, A. Umasankar, Solomon Umukoro, Nitin K. Upadhyay, Fazal ur Rehman, Vellingiri Vadivel, Patrícia Valentão, Andras Varga, Žužana Vaštag, Martha Verghese, Y. Vimala, Lloyd T. Walker, He-xiang Wang, Hengshan Wang, Kai Wang, Xiao-li Wang, Cornelius W. Wanjala, Francine K. Welty, Jack H. Wong, Lisa G. Wood, Teruyoshi Yanagita, Bao Yang, Xiujuan Ye, Xianghui Yi, Jau-Song Yu, Alam Zeb, Ye Zhang, Cheng-Jian Zheng, and Adel Zitoun
- Published
- 2011
- Full Text
- View/download PDF
11. Contributors
- Author
-
Ashkan Afshin, George L. Bakris, Christie M. Ballantyne, Ronny A. Bell, Jeffrey S. Berger, Deepak L. Bhatt, George L. Blackburn, Michael J. Blaha, Roger S. Blumenthal, Ariel Brautbar, Matthew J. Budoff, Gregory L. Burke, Javed Butler, Alison M. Coates, Mary C. Corretti, Rebecca B. Costello, Michael H. Davidson, Milind Y. Desai, William J. Elliott, R. Curtis Ellison, Edward Fisher, Puneet Gandotra, Vasiliki V. Georgiopoulou, Gary Gerstenblith, Ty J. Gluckman, M. Odette Gore, Kristina A. Harris, Alison M. Hill, P. Michael Ho, Paul N. Hopkins, Silvio E. Inzucchi, Heather M. Johnson, Steven R. Jones, Andreas P. Kalogeropoulos, Sekar Kathiresan, Chad Kliger, Penny M. Kris-Etherton, Peter O. Kwiterovich, Edward G. Lakatta, Donald M. Lloyd-Jones, John C. Longhurst, Russell V. Luepker, Thomas M. Maddox, Shaista Malik, Darren K. McGuire, C. Noel Bairey Merz, Michael Miller, Emile R. Mohler, Samia Mora, Kiran Musunuru, Christian D. Nagy, Samer S. Najjar, Vijay Nambi, Khurram Nasir, Raymond Oliva, Raza H. Orakzai, Gurusher S. Panjrath, Jessica M. Peña, Tamar Polonsky, Prabhakar Rajiah, Elizabeth V. Ratchford, Alan Rozanski, Arthur Schwartzbard, Amil M. Shah, Leslee J. Shaw, Chrisandra L. Shufelt, Sidney C. Smith, Kristina Spellman, Laurence S. Sperling, James H. Stein, Kerry J. Stewart, Peter P. Toth, Karol E. Watson, Howard Weintraub, Francine K. Welty, Mark A. Williams, Peter W.F. Wilson, Samuel Wollner, and Nathan D. Wong
- Published
- 2011
- Full Text
- View/download PDF
12. Effect of Soybean (Glycine max L.) on Hot Flashes, Blood Pressure, and Inflammation
- Author
-
Amna Ali, Sunny Jhamnani, Francine K. Welty, and Nguyen Nguyen
- Subjects
medicine.medical_specialty ,Allergy ,business.industry ,Saturated fat ,Isoflavones ,medicine.disease ,Prehypertension ,chemistry.chemical_compound ,Blood pressure ,Endocrinology ,chemistry ,Internal medicine ,medicine ,Phytoestrogens ,business ,Adverse effect ,Anaphylaxis - Abstract
Publisher Summary This chapter discusses certain medicinal effects of soybeans. Many potential benefits have been linked to the intake of soy products according to epidemiological investigations, such as on hot flashes, also known as “hot flushes,” and other menopausal symptoms, including the effect on blood pressure and inflammation. The soybean is a versatile legume that contains high-quality protein and minimal saturated fat and is an essential unique dietary source of isoflavones—a group of diphenolic compounds classified as phytoestrogens. Soy has received attention as an alternative to conventional hormone replacement therapy (HRT) largely because of these isoflavones. The estrogen-like effects of isoflavones in combination with low reported frequency of hot flashes has prompted the investigation of the effect of soy on menopausal symptoms. Soy nuts also decreased systolic and diastolic blood pressures in hypertensive, prehypertensive, and normotensive women. It lowered levels of LDLC and apoB in hypertensive, hyperlipidemic women. Soy nuts also lowered levels of inflammation. The main adverse effects of soy include gastrointestinal complaints. Soy is a common food causing allergy, with manifestations including urticaria, itching, hives, rash, diarrhea, dyspnea, diaphoresis, and anaphylaxis.
- Published
- 2011
- Full Text
- View/download PDF
13. The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease
- Author
-
Francine K. Welty
- Subjects
chemistry.chemical_compound ,medicine.medical_specialty ,Endocrinology ,Triglyceride ,chemistry ,business.industry ,Atherosclerotic cardiovascular disease ,Internal medicine ,Medicine ,Blood lipids ,business - Published
- 2011
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.